Teva acquires development rights to OGX-011

In a somewhat surprising announcement, Teva Pharmaceuticals — best known as the world’s largest manufacturer and marketer of generic drugs — has acquired the global development and marketing rights to OGX-011 from OncoGenex.

Teva has built a successful group that (to date) has focused on the development of innovative drugs for the treatment of neurological disorders — most visibly through the global marketing of glatiramer acetate (Copaxone) for multiple sclerosis and rasagiline (Azilect) for Parkinson’s disease. However, the company has had research interests in oncology for a while, and the in-licensing of OGX-011 may be a means to jump-start the development of an oncology marketing group.

As regular readers will know, OGX-011 is currently expected to enter Phase III clinical trials, in comjunction wsith docetaxel (Taxotere) for the treatment of men with castration-resistant prostate cancer (CRPC). Data available to date suggest that OGX-011 has significant potential for treatment of these men — even for those who have progressed after a first round of docetaxel-based chemotherapy.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: